NightHawk Biosciences, Inc.(NYSE Amex Equities : HTBX)
HTBX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||1.40%||179.46||0.7%||$1371.52m|
|BMY||Bristol-Myers Squibb Co.||0.63%||76.67||1.0%||$1204.82m|
|MRK||Merck & Co., Inc.||0.45%||93.98||0.7%||$1144.89m|
|LLY||Eli Lilly & Co.||1.25%||302.57||1.1%||$903.32m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||0.66%||142.97||0.0%||$461.53m|
|HZNP||Horizon Therapeutics Plc||-3.29%||87.38||5.4%||$193.81m|
|NVO||Novo Nordisk A/S||0.07%||107.83||0.1%||$190.87m|
NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.